A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig and the best treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, obrixtamig is given to people for the first time. Interim clinical data are available for obrixtamig. Participants get obrixtamig either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza: rak płuc małokomórkowy, rak płuca z dużymi komórkami neuroendokrynnym lub inne nowotwory neuroendokrynne
- •Nowotwór musi być pozytywny na marker DLL3 (potwierdzone badaniem tkanki)
- •Nowotwór jest zaawansowany lub rozszerzony, nie można go leczyć poprzez operację
- •Pacjent wcześniej nie odpowiedział na dostępne standardowe leczenie lub nie kwalifikuje się do niego
- •Pacjent musi być w dobrym ogólnym stanie zdrowia (ECOG 0-1)
- •Przynajmniej jeden mierzalny guz poza mózgiem
- •Pacjenci z przerzutami do mózgu mogą uczestniczyć, jeśli radiotherapia lub operacja były wykonane co najmniej 2 tygodnie przed badaniem
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (12)
Winship Cancer Institute
Atlanta, United States
University of Maryland School of Medicine
Baltimore, United States
Washington University School of Medicine
St Louis, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Universitätsklinikum Köln (AöR)
Cologne, Germany
Technische Universität Dresden
Dresden, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Hospital del Mar
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Trial contact
Boehringer Ingelheim
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.